Pegcetacoplan has shown superior efficacy over eculizumab in patients with PNH with persistent anemia despite C5 inhibition [9], yet human pregnancy data are limited to a single case report [13], which did not include pharmacokinetic analysis. This evidence concerns the gene C5 and anemia (phenotype).